Literature DB >> 33501446

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma.

Constantinos Kurt Wibmer1, Frances Ayres1, Tandile Hermanus1, Mashudu Madzivhandila1, Prudence Kgagudi1, Brent Oosthuysen1, Bronwen E Lambson1,2, Tulio de Oliveira3, Marion Vermeulen4, Karin van der Berg4,5, Theresa Rossouw6, Michael Boswell7, Veronica Ueckermann7, Susan Meiring1, Anne von Gottberg1,8, Cheryl Cohen1,9, Lynn Morris1,2, Jinal N Bhiman1,10, Penny L Moore1,2.   

Abstract

SARS-CoV-2 501Y.V2 (B.1.351), a novel lineage of coronavirus causing COVID-19, contains substitutions in two immunodominant domains of the spike protein. Here, we show that pseudovirus expressing 501Y.V2 spike protein completely escapes three classes of therapeutically relevant antibodies. This pseudovirus also exhibits substantial to complete escape from neutralization, but not binding, by convalescent plasma. These data highlight the prospect of reinfection with antigenically distinct variants and foreshadows reduced efficacy of spike-based vaccines.

Entities:  

Year:  2021        PMID： 33501446      PMCID： PMC7836116          DOI： 10.1101/2021.01.18.427166

Source DB:  PubMed          Journal:  bioRxiv


  19 in total

1.  Theoretically quantifying the direct and indirect benefits of vaccination against SARS-CoV-2 in terms of avoided deaths.

Authors:  Greg Scutt; Mike Cross; David Waxman
Journal:  Sci Rep       Date:  2022-05-25       Impact factor: 4.996

Review 2.  Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines.

Authors:  Daniele Focosi; Fabrizio Maggi
Journal:  Rev Med Virol       Date:  2021-03-16       Impact factor: 11.043

3.  SARS-CoV-2 Variants of Concern in the United States-Challenges and Opportunities.

Authors:  Rochelle P Walensky; Henry T Walke; Anthony S Fauci
Journal:  JAMA       Date:  2021-03-16       Impact factor: 157.335

Review 4.  SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?

Authors:  Saborni Chakraborty; Vamsee Mallajosyula; Cristina M Tato; Gene S Tan; Taia T Wang
Journal:  Adv Drug Deliv Rev       Date:  2021-01-20       Impact factor: 17.873

Review 5.  On the road to ending the COVID-19 pandemic: Are we there yet?

Authors:  James Brett Case; Emma S Winkler; John M Errico; Michael S Diamond
Journal:  Virology       Date:  2021-02-26       Impact factor: 3.513

Review 6.  One year into the pandemic: Short-term evolution of SARS-CoV-2 and emergence of new lineages.

Authors:  Fernando González-Candelas; Marie-Anne Shaw; Tung Phan; Urmila Kulkarni-Kale; Dimitrios Paraskevis; Fabio Luciani; Hirokazu Kimura; Manuela Sironi
Journal:  Infect Genet Evol       Date:  2021-04-26       Impact factor: 4.393

Review 7.  The variant gambit: COVID-19's next move.

Authors:  Jessica A Plante; Brooke M Mitchell; Kenneth S Plante; Kari Debbink; Scott C Weaver; Vineet D Menachery
Journal:  Cell Host Microbe       Date:  2021-03-01       Impact factor: 31.316

8.  Longitudinal and proteome-wide analyses of antibodies in COVID-19 patients reveal features of the humoral immune response to SARS-CoV-2.

Authors:  Jianxin Wang; Yongfei Yang; Te Liang; Ning Yang; Tao Li; Chang Zheng; Nianzhi Ning; Deyan Luo; Xiaolan Yang; Zhili He; Guang Yang; Bo Li; Jie Gao; Wenjing Yu; Saisai Gong; Yanyu Huang; Jiajia Li; Hongye Wang; Hao Zhang; Tian Zhang; Peiran Li; Yongli Li; Jiayu Dai; Xiaomei Zhang; Boan Li; Xiaobo Yu; Hui Wang
Journal:  J Adv Res       Date:  2021-07-27       Impact factor: 12.822

9.  Public health implications of SARS-CoV-2 variants of concern: a rapid scoping review.

Authors:  Mari Somerville; Janet A Curran; Justine Dol; Leah Boulos; Lynora Saxinger; Alexander Doroshenko; Stephanie Hastings; Bearach Reynolds; Allyson J Gallant; Hwayeon Danielle Shin; Helen Wong; Daniel Crowther; Marilyn Macdonald; Ruth Martin-Misener; Jeannette Comeau; Holly McCulloch; Andrea C Tricco
Journal:  BMJ Open       Date:  2021-12-02       Impact factor: 3.006

10.  One or two dose regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease burden in nonhuman primate challenge model.

Authors:  Karen E Gooch; Trevor R F Smith; Francisco J Salguero; Susan A Fotheringham; Robert J Watson; Mike J Dennis; Alastair Handley; Holly E Humphries; Stephanie Longet; Tom Tipton; Charlotte Sarfas; Laura Sibley; Gillian S Slack; Emma Rayner; Kathryn A Ryan; Katherine Schultheis; Stephanie J Ramos; Andrew White; Sue Charlton; Sally A Sharpe; Fergus Gleeson; Laurent M Humeau; Yper Hall; Kate E Broderick; Miles W Carroll
Journal:  Vaccine       Date:  2021-06-23       Impact factor: 4.169
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.